Protracted fever after infliximab induction therapy in a patient with ulcerative colitis (clinical case)

Inflammatory bowel diseases (ulcerative colitis and Crohn’s disease) tend to increase in frequency and prevalence worldwide and lead to a significant reduction in quality of life with a complicated course. Intravenous administration of corticosteroids in acute severe ulcerative colitis is effective in 60–70 % of cases. Rescue therapy for patients with steroid‐refractory and steroid-dependence attacks is effective for reducing colectomy or colproctectomy and improves long-term treatment outcomes. Despite the proven efficacy of infliximab, limitations to the use of monoclonal antibodies are adverse reactions to the administration of genetically engineered biologic therapy (GEBT), both well-known and studied, and rare.
The aim of the study. To analyze a case of an extremely rare and paradoxical incurable hyperergic reaction that occurred after using genetically engineered biological therapy with tumor necrosis factor alpha blockers in a patient suffering from ulcerative colitis.
Materials and methods. We carried out the search in the PubMed, Embase, Scopus and Medline databases until November 1, 2022 using the following keywords: inflammatory bowel disease, ulcerative colitis (UC), anti-tumor necrosis factor α (antiTNFα), infliximab, fever, adverse events. In the scientific electronic library eLIBRARY, a search was made for Russian-language publications using similar queries in Russian. We analyzed the patient’s medical records from 03.06.2013 up to the present day; the patient signed an informed consent for the publication and discussion of the presented data.
Conclusion. The widespread use of GEBT in the treatment of autoimmune and autoinflammatory diseases leads to the accumulation of both positive and negative experience of clinicians in real clinical practice. The officially described adverse events in the appointment of any drug suggest options for their prevention and treatment. Atypical manifestations or casuistic cases must be systematized for further fundamental pathophysiological studies.

1. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1963; 4(4): 299-315. doi: 10.1136/gut.4.4.299

2. Fornaro R, Caratto M, Barbruni G, Fornaro F, Salerno A, Giovinazzo D, et al. Surgical and medical treatment in patients with acute severe ulcerative colitis. J Dig Dis. 2015; 16(10): 558-567. doi: 10.1111/1751-2980.12278

3. Ramakrishna BS, Choudhuri G, Kochhar R. Natural history of first episode of acute severe colitis. Trop Gastroenterol. 2014; 35(Suppl 1): S9-S11. doi: 10.7869/tg.176

4. Achkasov SI, Shapina MV, Veselov VV, Vardanyan AV, Mingazov AF, Ponomarenko AA. Predictors of colectomy in patients with «extremely severe» ulcerative colitis. Koloproktologia. 2020; 19(3): 37-48. (In Russ.). doi: 10.33878/2073-7556-2020-19-3-37-48

5. Duijvis N, ten Hove A, Ponsioen C, van den Brink G, Te Velde A, D’Haens G, et al. Lower long-term colectomy rates with IFX than with CsA treatment in moderate to severe UC. J Crohns Colitis. 2015; 9(Suppl 1): S53-S54. doi: 10.1093/ecco-jcc/jju027.080

6. Song EM, Lee SH, Chang K, Hwang SW, Park SH, Yang DH, et al. Long-term outcomes of cyclosporine A and infliximab treatment for the management of steroid-refractory acute severe ulcerative colitis. J Crohns Colitis. 2018; 12(Suppl 1): S182. doi: 10.1093/ecco-jcc/jjx180.294

7. Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, et al. Vedolizumab and anti-tumour necrosis factor α real-world outcomes in biologic-naive inflammatory bowel disease patients: Results from the EVOLVE study. J Crohns Colitis. 2021; 15(10): 1694-1706. doi: 10.1093/ecco-jcc/jjab058

8. Highlights of prescribing information. Infliximab for injection, for intravenous use. Initial U.S. approval. 1998. URL: https://www.accessdata.fda.gov [date of access: 25.10.2022].

9. Connor V. Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression. Rheumatol Int. 2011; 31(3): 327-337. doi: 10.1007/s00296-009-1292-x

10. Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology. 2005; 128(7): 1805-1811. doi: 10.1053/j.gastro.2005.03.003

11. Tassiopoulos S, Benopoulou O, Mytilineou E, Andreopoulos A, Vaiopoulos G. Late onset of long-lasting fever as a sole complication of treatment with anti-TNFalpha. Clin Exp Rheumatol. 2005; 23(1): 122-123.

12. Katz J, Frank M. Prolonged fever after Infliximab infusion. World J Gastrointest Pharmacol Ther. 2012; 3(3): 34-35. doi: 10.4292/wjgpt.v3.i3.34

13. Colombel JF, Loftus EV, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn’s disease: The Mayo clinic experience in 500 patients. Gastroenterology. 2004; 126(1): 19-31. doi: 10.1053/j.gastro.2003.10.047

14. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353(23): 2462-2476. doi: 10.1056/NEJMoa050516

15. Hopkins PM, Rüffert H, Snoeck MM, Girard T, Glahn KP, Ellis FR, et al. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth. 2015; 115(4): 531-539. doi: 10.1093/bja/aev225

16. Yu H, Tan L, Teng Y, Xu Z, Xiao K, Yin J, t al. The First National Remote Emergency System for Malignant Hyperthermia (MH-NRES) in China: Protocol for the design, development, and evaluation of a WeChat applet. JMIR Res Protoc. 2022; 11(6): e37084. doi: 10.2196/37084